Free Trial

Novartis (NVS) SEC Filings & 10K Form

Novartis logo
$118.59 +0.57 (+0.48%)
Closing price 06/10/2025 03:59 PM Eastern
Extended Trading
$118.60 +0.01 (+0.01%)
As of 06/10/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Novartis SEC Filings

DateFilerForm TypeView
06/02/2025
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/27/2025
5:56 AM
Novartis (Filed by)
Regulus Therapeutics Inc. (Subject)
Form SC TO-T
05/01/2025
4:00 PM
Novartis (Filed by)
Regulus Therapeutics Inc. (Subject)
Form SC TO-C
04/30/2025
4:00 PM
Novartis (Filed by)
Regulus Therapeutics Inc. (Subject)
Form SC TO-C
04/29/2025
5:01 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/02/2025
8:35 PM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/28/2025
1:01 PM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/31/2025
6:07 AM
Novartis (Filer)
Form 20-F
Registration statement / Annual report / Transition report  
01/31/2025
6:12 AM
Novartis (Filer)
Form IRANNOTICE
01/31/2025
6:14 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/31/2025
6:16 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/30/2024
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/25/2024
9:20 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/29/2024
5:20 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/18/2024
3:38 PM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/17/2024
4:08 PM
Novartis (Filer)
Novartis Capital CORP (Filer)
Form 424B5
09/17/2024
1:05 PM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/16/2024
4:12 PM
Novartis (Subject)
Form FWP
09/16/2024
7:44 AM
Novartis (Filer)
Novartis Capital CORP (Filer)
Form 424B5
09/16/2024
7:12 AM
Novartis (Filer)
Novartis Capital CORP (Filer)
Form F-3ASR
08/15/2024
3:30 PM
MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
Form SC 13D/A
08/13/2024
3:31 PM
MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
Form SC TO-T/A
08/12/2024
2:30 PM
Kowalski Robert William (Reporting)
Novartis (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/07/2024
7:12 PM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/07/2024
3:30 PM
MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
Form SC TO-T/A
08/02/2024
3:30 PM
MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
Form SC TO-T/A
08/01/2024
3:30 PM
MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
Form SC TO-T/A
07/31/2024
3:30 PM
MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
Form SC TO-T/A
07/30/2024
3:30 PM
MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
Form SC TO-T/A
07/29/2024
3:30 PM
MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
Form SC TO-T/A
07/25/2024
3:30 PM
MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
Form SC TO-T/A
07/18/2024
3:30 PM
MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
Form SC TO-T/A
07/18/2024
5:09 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/11/2024
3:30 PM
MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
Form SC TO-T/A
07/05/2024
5:02 AM
MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
Form SC TO-T
06/21/2024
3:30 PM
MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
Form SC 13D/A
06/20/2024
2:38 PM
MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
Form SC TO-C
06/17/2024
3:30 PM
MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
Form SC 13D/A
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NYSE:NVS) was last updated on 6/11/2025 by MarketBeat.com Staff
From Our Partners